Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 3/20 | 0.35 |
| ▸ | DRD3 | P35462 | 3/20 | 0.35 |
| ▸ | HTR1A | P08908 | 2/20 | 0.33 |
| ▸ | HTR7 | P34969 | 2/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | LOX | P28300 | 1/20 | 0.32 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6952511 | 1.00 | TRPV1 (0.36) | TRPV1DRD2DRD3HTR1AHTR7 | |
| SCHEMBL29365060 | 1.00 | TRPV1 (0.36) | TRPV1DRD2DRD3HTR1AHTR7 | |
| SCHEMBL3424340 | 1.00 | TRPV1 (0.36) | TRPV1DRD2DRD3HTR1AHTR7 | |
| SCHEMBL29365669 | 1.00 | TRPV1 (0.36) | TRPV1DRD2DRD3HTR1AHTR7 | |
| SCHEMBL8611416 | 0.89 | TRPV1 (0.33) | TRPV1DRD2DRD3HCAR2MAOA | |
| SCHEMBL8615203 | 0.87 | TRPV1 (0.34) | TRPV1DRD2DRD3HTR1AHTR7 | |
| SCHEMBL6957852 | 0.85 | TRPV1 (0.41) | TRPV1HTR1AHTR7HCAR2CYP1A2 | |
| SCHEMBL6958627 | 0.85 | TRPV1 (0.41) | TRPV1HTR1AHTR7HCAR2CYP1A2 | |
| SCHEMBL8613526 | 0.82 | EPAS1 (0.33) | TRPV1HCAR2MAOAMAOBLOX | |
| SCHEMBL19266090 | 0.78 | DRD2 (0.39) | DRD2DRD3HTR1AHTR7MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113981013-B | Biocatalysis preparation method of chiral tetrahydronaphthalene-2-alcohol compound | 上海升华医药科技有限公司 | 2024-02-20 | — | — | CN | claimed |
| CN-113981013-A | Biocatalytic preparation method of chiral tetrahydronaphthalene-2-alcohol compound | 寰酶生物技术(上海)有限公司 | 2022-01-28 | — | — | CN | claimed |
| CN-111018663-A | Nepitastat important intermediate and enzyme catalytic synthesis method thereof | 苏州凯瑞医药科技有限公司 | 2020-04-17 | — | — | CN | claimed |
| CN-113981013-B | Biocatalysis preparation method of chiral tetrahydronaphthalene-2-alcohol compound | 上海升华医药科技有限公司 | 2024-02-20 | — | — | CN | disclosed |
| CN-113981013-B | Biocatalysis preparation method of chiral tetrahydronaphthalene-2-alcohol compound | 上海升华医药科技有限公司 | 2024-02-20 | — | — | CN | disclosed |
| CN-116063186-A | Process and intermediates for the preparation of (S) -2-amino-5, 7-difluoro-1, 2,3, 4-tetrahydronaphthalene hydrogen halides | 江苏亚虹医药科技股份有限公司 | 2023-05-05 | — | — | CN | disclosed |
| CN-113981013-A | Biocatalytic preparation method of chiral tetrahydronaphthalene-2-alcohol compound | 寰酶生物技术(上海)有限公司 | 2022-01-28 | — | — | CN | disclosed |
| CN-113981013-A | Biocatalytic preparation method of chiral tetrahydronaphthalene-2-alcohol compound | 寰酶生物技术(上海)有限公司 | 2022-01-28 | — | — | CN | disclosed |
| US-20200383951-A1 | METHODS FOR TREATING DEPENDENCE | BIOTIE THERAPIES INC (US) | 2020-12-10 | — | — | US | disclosed |
| CN-111018663-A | Nepitastat important intermediate and enzyme catalytic synthesis method thereof | 苏州凯瑞医药科技有限公司 | 2020-04-17 | — | — | CN | disclosed |
| CN-111018663-A | Nepitastat important intermediate and enzyme catalytic synthesis method thereof | 苏州凯瑞医药科技有限公司 | 2020-04-17 | — | — | CN | disclosed |
| EP-2182804-B1 | METHODS FOR TREATING DEPENDENCE | BIOTIE THERAPIES INC (US) | 2017-05-24 | — | — | EP | disclosed |
| US-20140099336-A1 | Methods for Treating Dependence | BIOTIE THERAPIES, INC. (US) | 2014-04-10 | — | — | US | disclosed |
| US-20090054403-A1 | Treatment of Post-Traumatic Stress Disorder | SYNOSIA THERAPEUTICS (US) | 2009-02-26 | — | — | US | disclosed |
| US-20090041800-A1 | Methods for Treating Dependence | SYNOSIA THERAPEUTICS, INC. (US) | 2009-02-12 | — | — | US | disclosed |
| EP-0757677-B1 | BENZOCYCLOHEXYLIMIDAZOLETHIONE DERIVATIVES | SYNTEX LLC (US) | 2003-06-18 | — | — | EP | disclosed |
| US-5719280-A | REACTING AMINE SUBSTITUTED BENZOCYCLOALKANE WITH DIALKYLOXYACETALDEHYDE IN PRESENCE OF REDUCING AGENT OR CATALYTIC HYDROGENATION, TREATING WITH THIOCYANIC ACID | SYNTEX (U.S.A.) INC. (US) | 1998-02-17 | — | — | US | disclosed |
| EP-0757677-A1 | BENZOCYCLOALKYLAZOLETHIONE DERIVATIVES | SYNTEX (U.S.A.) INC. (US) | 1997-02-12 | — | — | EP | disclosed |
| US-5538988-A | CARDIOVASCULAR DISORDERS AND DOPAMINE HYDROLASE ENZYME INHIBITORS | SYNTEX (U.S.A.) INC. | 1996-07-23 | — | — | US | disclosed |
| WO-1995029165-A2 | BENZOCYCLOALKYLAZ0LETHIONE DERIVATIVES AS DOPAMIN BETA-HYDROXYLASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1995-11-02 | — | — | WO | disclosed |